1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma
    Meeting Abstract

    Leonard, J. P.; LaCasce, A.; Smith, M. R.; Noy, A.; Yap, J. T.; Van Den Abbeele, A. D.; Yu, J. Q.; Chen-Kiang, S.; Ely, S. A.; Vallabhajosula, S.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors
    Meeting Abstract

    Kurzrock, R.; Hamlin, P.; Gordon, M.; Hong, D.; Fu, S.; Younes, A.; Hannah, A.; Palladino, M. A.; Spear, M. A.; Aghajanian, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Validation of the international harmonization project (IHP) guidelines in early stage Hodgkin lymphoma (HL) treated with adriamycin, vinblastine and gemcitabine (AVG) (CALGB 50203): Early results
    Meeting Abstract

    Kostakoglu, L.; Straus, D. J.; Schoder, H.; LaCasce, A. S.; Bartlett, N. L.; Hall, N.; Johnson, J. L.; Jung, S. H.; Canellos, G. P.; Schwartz, L. H.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Efficacy of extracorporeal photopheresis (ECP) monotherapy in the treatment of cutaneous T cell lymphoma (CTCL)
    Meeting Abstract

    Knobler, R.; Foss, F.; Duvic, M.; Straus, D.; Horwitz, S.; Zain, J.; Kuzel, T.; Querfeld, C.; Campbell, K.; Geskin, L.
    Journal of Investigative Dermatology (2008)

    Fulltext@MSK | Save
  • A phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lympboprolifierative malignancies
    Meeting Abstract

    Horwitz, S. M.; Vose, J. M.; Advani, R.; Sankhala, K.; Padmanabhan, S.; Hamlin, P. A.; Chen, A.; Wilroy, S.; Zain, J. M.; Wright, D.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Clofarabine is active in peripheral T-cell lymphomas: Results of the phase I portion of a phase I/II study
    Meeting Abstract

    Horwitz, S.; Mulford, D.; Paul, H.; Weissbrot, H.; Zelenetz, A. D.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose-finding trial
    Meeting Abstract

    Horwitz, S. M.; Duvic, M.; Kim, Y.; Zain, J. M.; Lechowicz, M. J.; Myskowski, P.; Weissbrot, H.; Wright, D.; Chance, L.; Koutsoukos, T.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial
    Meeting Abstract

    Horwitz, S.; Duvic, M.; Kim, Y.; Chance, L.; Myskowski, P.; Talpur, R.; Morales, A.; Saunders, M.; O'connor, O.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Influence of post-second-line chemotherapy PET Imaging and involved field radiotherapy prior to high dose therapy on outcomes of relapsed or refractory diffuse large B cell lymphoma
    Meeting Abstract

    Hoppe, B. S.; Moskowitz, C. H.; Zhang, Z.; Kewalramani, T.; Maragulia, J. C.; Rice, R. D.; Reiner, A. S.; Hamlin, P. A.; Zelenetz, A. D.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2008)

    Fulltext@MSK | Save
  • Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL
    Meeting Abstract

    Hamlin, P. A.; Moskowitz, C. H.; Wegner, B.; Noy, A.; Gerecitano, J.; Palomba, M. L.; Portlock, C.; Straus, D.; Pro, B.; Fayad, L.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save